Scholarlink

<p>This study presents a novel radiolabeling technique for [<sup>161</sup>Tb]-PSMA-617 in metastatic castration-resistant prostate cancer (mCRPC). The research focused on assessing the radiochemical yield, in vivo stability, and pharmacokinetics of [<sup>116</sup>&#xa0;Tb]-PSMA-617 in a clinical setting. Using a sodium acetate buffer and ascorbic acid, a high radiochemical yield (97.98% ± 2.01) was achieved, ensuring stability and purity. The therapy was evaluated to a 77-year-old mCRPC patient resistant to [177Lu]-PSMA-617, showing favorable biodistribution and urinary excretion. Despite initial stability, disease progression occurred, with a TP53 mutation identified via liquid biopsy. While the method holds promise for targeted radionuclide therapy, resistance mechanisms remain a challenge, necessitating further research for optimized patient selection and treatment strategies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Terbium-161 PSMA therapy in mCRPC patient based on an optimized radiolabeling protocol

  • 期刊论文

  • 发表日期：

    2025年9月1日

查看全文
  • Ceren Sezgin,
  • Emre Uygur,
  • Yasemin Parlak,
  • Busra Karatay,
  • Sabri Barutca,
  • Ahmet Dirican,
  • Tevfik Sinan Sozen,
  • Guven Arslan,
  • Coskun Harmansah,
  • Turkay Toklu,
  • Ugur Avcibasi,
  • Zumrut Biber Muftuler,
  • Omer Aras,
  • Gul Gumuser

摘要

This study presents a novel radiolabeling technique for [161Tb]-PSMA-617 in metastatic castration-resistant prostate cancer (mCRPC). The research focused on assessing the radiochemical yield, in vivo stability, and pharmacokinetics of [116 Tb]-PSMA-617 in a clinical setting. Using a sodium acetate buffer and ascorbic acid, a high radiochemical yield (97.98% ± 2.01) was achieved, ensuring stability and purity. The therapy was evaluated to a 77-year-old mCRPC patient resistant to [177Lu]-PSMA-617, showing favorable biodistribution and urinary excretion. Despite initial stability, disease progression occurred, with a TP53 mutation identified via liquid biopsy. While the method holds promise for targeted radionuclide therapy, resistance mechanisms remain a challenge, necessitating further research for optimized patient selection and treatment strategies.